Jamie Skipper | Former, ONC - Patient Centered Outcomes Research/HIT Policy

Jamie Skipper, Former, ONC - Patient Centered Outcomes Research/HIT Policy, HSS

Dr. Jamie Skipper, RN, PhD, is currently a Healthcare/Health IT Policy Advisor and Strategist at Elevation Health Consulting where she advises public and private stakeholders across the healthcare arena to strategically improve health outcomes with a person-centric motto through leveraging, improving or building health technology.   Dr. Skipper was a former Senior Scientist at the Office of the National Coordinator for Health IT (ONC) and ONC’s Patient Centered Outcomes Research (PCOR) Coordinator leading efforts around the concepts of “learning health system” and “PCOR.”  Prior to taking on the role as ONC’s PCOR Coordinator, Dr. Skipper served as the Coordinator for the ONC’s Standards & Interoperability (S&I) Framework. Before coming to ONC, Dr. Skipper served as a healthcare and health IT Legislative Assistant on Capitol Hill and as Program Director for the Cardiac Myopathy grant portfolio at the National Heart, Lung and Blood Institute (NHLBI) at NIH.  Dr. Skipper has a Ph.D. in Cardiac Physiology from the University of Glasgow, Scotland and a B.S.N. from Marquette University.


Pharma Pricing & Market Access USA Day 1 @ 11:20

FIRESIDE CHAT: Future tools and technologies for evidence generation

  • A widely cited study for the National Institute of Standards & Technology (NIST) reports that inadequate testing methods and tools annually cost the U.S. economy between $22.2 and $59.5 billion, with roughly half of these costs borne by software developers in the form of extra testing software users in the form of failure avoidance and mitigation efforts
  • How to implement new tools: Demonstrating ethics, value and enabling it to connect databases
  • Ensuring the required standard of evidence is met
  • Exploring data mining, signal detection, patient portals, N of 1 studies, insilico methodologies

Pharma Pricing & Market Access USA Day 2 @ 09:00

Keynote address: The future of evidence, pricing and reimbursement in the US healthcare system and what it means to you

  • Impact of the Trump administration on the payer/buyer relationship 
  • The impact of leveraging buying power for Medicare
  • Will drug prices be significantly reduced as a result?
  • What will the effects on global R&D be?

back to speakers